December 17, 2025 12:00 pm
LVBCH OBESITY LEARNING COLLABORATIVE RETURNS WITH A SPECIAL WEBINAR: “LVBCH OBESITY LEARNING COLLABORATIVE: ORAL SEMAGLUTIDE PRE-APPROVAL EXCHANGE PRESENTATION”
EMPLOYER MEMBERS ONLY
About the Obesity Learning Collaborative: The obesity learning collaborative is an ongoing peer-to-peer discussion and educational series featuring local employers and clinical experts on obesity topics. For the past three years, these sessions have focused on comprehensive obesity care while also taking a deeper dive into the landscape around GLP-1s and other anti-obesity medications.
Most recently, there has been a lot of buzz in the media about oral alternatives to these medications potentially becoming available in 2026.
LVBCH is pleased to partner with Novo Nordisk, and to welcome back Niki Patel, Pharm D, to provide employer members with early look at information related to oral semaglutide for obesity.
This “Pre-Approval Exchange Presentation” will provide you with information about oral semaglutide 25 mg, an investigative therapy developed by Novo Nordisk.
Oral semaglutide 25 mg is an investigational product and not approved by the US Food and Drug Administration for use, as its safety and effectiveness have not been established. This program will present preapproval information for oral semaglutide 25 mg, which was studied in adults with obesity or overweight with at least 1 weight-related comorbidity, in addition to increased physical activity and a reduced calorie diet.
Oral Semaglutide Pre-Approval Exchange Presentation
This “Pre-Approval Exchange Presentation” will provide you with information about oral semaglutide 25 mg, an investigative therapy developed by Novo Nordisk.
Oral semaglutide 25 mg is an investigational product and not approved by the US Food and Drug Administration for use, as its safety and effectiveness have not been established.
This program will present preapproval information for oral semaglutide 25 mg, which was studied in adults with obesity or overweight with at least 1 weight-related comorbidity, in addition to increased physical activity and a reduced calorie diet.
Niki Patel, PharmD, MBA, CDCES
Dr. Niki Patel is currently a Medical Accounts Director with Novo Nordisk, focused on education and access to therapies in cardiometabolic diseases across the NorthEast. In this role, Dr. Patel spends her time consulting employers, health plans and state government (Medicaid/Medicare) organizations responsible for drug formulary decisions impacting millions of patients throughout the country. In addition, Dr. Patel engages with large employer and coalitions such as Chubb, Quest, GPBCH, NEBGH, and LVBCH who are attentive to the clinical crisis of obesity and diabetes in employees. Her aim is to assist organizations in improving employees’ health via appropriate medical management. She served as keynote speaker at multiple conferences and roundtables over the past few years.
More recently, Dr. Patel has been an advocate on health equity and its impact on patients with chronic conditions.
Over the years, Niki has received many honors including: 2015 NorthEast Customer Engagement Award, the 2015 and 2016 Take Action Challenge Grants, 2018 Medical Affairs Circle of Excellence the highest award given to clinical employees in the organization, and a company innovation challenge.
In addition, she serves as Adjunct Professor at Long Island University where she founded the first Intro to Pharmaceutical Industry course, serves as advisor for a pharmacy student leadership organization and as preceptor for pharmacy rotation students. She also serves on the Education Committee for the Pharmacy Quality Alliance, and previously was on the board of NYCSHP where she organized their 1st Medical Mission to her hometown in India. She also volunteers at a non-profit in Community and Public Affairs to support charitable work including health fairs, educational seminars and programs for underserved communities. She is passionate about patient advocacy, health equity, and education.
PRESENTING SPONSOR
